VentriPoint Diagnostics Ltd.

VentriPoint Diagnostics Ltd.

July 11, 2011 08:30 ET

Dr. Robyn J. Barst to Lead Pulmonary Hypertension Clinical Development Program for Validation of the VentriPoint VMS™ Heart Analysis System

Five Clinical Sites in USA Selected for Validation Study for FDA

SEATTLE, WASHINGTON--(Marketwire - July 11, 2011) - VentriPoint Diagnostics Ltd. ("VentriPoint") (TSX VENTURE:VPT)(PINK SHEETS:VPTDF) is pleased to announce that Dr. Robyn J. Barst will be the Program Director for VentriPoint's pulmonary hypertension (PH) clinical development program. Under her direction, the clinical protocols have been finalized and the clinical PH investigators and PH sites identified. VentriPoint expects to initiate the PH pilot study this summer and the PH Clinical Validation Pivotal Study needed for FDA submission this fall. Dr. Barst will also serve as the Principal Investigator for the studies.

"Now that I understand more about how the VMS™ can revolutionize our ability to assess disease severity and optimize care for patients with pulmonary hypertension, I welcome the opportunity to lead a team to bring this analytical tool into clinical use, " stated Dr. Barst. "I believe VentriPoint's VMS™ can become an important clinical tool, especially where MRI and/or contrast enhanced ultrasound do not adequately provide the critical information to determine the correct treatment."

The Company will begin to install its VMS™ heart analysis systems at each of the five PH medical centers participating in the clinical development program immediately upon receiving the requisite approvals and executing the research agreements. The sites and the lead investigator at each site will be announced once the agreements have been executed. The Clinical Validation Pivotal Study for PH will compare the VMS™ against MRI to verify that 2D-ultrasound with VMS™ is at least as good or better than MRI in assessing the necessary parameters of disease severity in order to optimally treat patients with pulmonary arterial hypertension.

"We are most fortunate to have Dr. Barst as the overall Program Director for our PH program. She is a recognized expert in clinical PH development studies and has the respect of the entire PH community," stated Dr. George Adams, CEO of VentriPoint. "PH is a $1B opportunity where 2D ultrasound and VMS™ can become the 'standard of care' in this growing patient population."

About Pulmonary Hypertension

Pulmonary arterial hypertension (PAH) is the most serious form of the five recognized groups of pulmonary hypertension. PAH is a devastating disease with an average lifespan of less than 3 years after diagnosis if untreated. It affects individuals of all ages from infancy to the elderly. Although treatment started early after detection appears more effective than when started later, the majority of patients with PAH continue to be diagnosed too late for treatment to be fully effective. PAH can occur for no known reason but will typically occur in association with many common conditions such as chronic liver disease and liver cirrhosis; connective tissue disorders such as scleroderma or systemic lupus erythematosus (lupus); congenital heart disease (even if repaired) and HIV. With increasing availability of effective therapies, and evidence-based treatment guidelines recommending starting treatment early, tests enabling detection as early as possible should prove invaluable.

About Dr. Robyn J. Barst

Dr. Barst received her undergraduate degree from the University of Rochester, Rochester, NY and her medical degree (Alpha Omega Alpha and the Distinguished Medical Alumnus Award of the School of Medicine) from the University of North Carolina, Chapel Hill, NC. She completed a residency in pediatrics, and two fellowships in pediatric cardiology and pulmonary medicine at Columbia University College of Physicians & Surgeons in New York, NY. Following her training, Dr. Barst was recipient of the AHA Clinician-Scientist Award and the NHLBI Clinical Investigator Award.

Dr. Barst founded the first pediatric and adult pulmonary hypertension center in 1982 at Columbia University and served as its director until 2008. She serves as a scientific advisor to pharmaceutical companies worldwide developing novel drugs for pulmonary hypertension. She is a consultant to the FDA, the EMEA and the NHLBI. She also served as Chair of the AHA's Council on Cardiovascular Disease in the Young.

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. The VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™ heart analysis system and VentriPoint is pursuing the US-FDA approval through the 510(k) process.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information